Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00003224 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00003224 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With a Synthetic Melanoma Peptide in Patients With High Risk Melanoma |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | QS21, IFA (incomplete Freund's adjuvant), p946, p946/tet-p, Tet-p |
| Enrollment | 22 |
| Start date | Feb 1, 1996 |
| Primary completion | Aug 1, 2000 |
| First posted | Aug 25, 2004 |
| Last update posted | Nov 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: